PCSK9 and cardiovascular disorder: Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (i) are a class of lipid-lowering drugs promoting a marked decrease in low-density lipoprotein (LDL)-cholesterol and demonstrated to reduce the incidence of cardiovascular diseases (CVD) in patients not-at-target with other therapies or intolerant to statins 1.